ArticleTherapeutics and clinical risk management2025
Association of Serum Cholinesterase with Contrast-Associated Acute Kidney Injury and Adverse Outcomes in Percutaneous Coronary Intervention Patients.
Article in Therapeutics and clinical risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Serum cholinesterase (SChE) is a pleiotropic biomarker that is closely related to malnutrition, systemic inflammation, and hepatocyte injury. However, the utility of SChE in patients undergoing percutaneous coronary intervention (PCI) remains unclear. This study sought to investigate the associations between SChE and contrast-associated acute kidney injury (CA-AKI) as well as mortality in patients undergoing PCI. Patients and Methods: We retrospectively observed 1,696 patients at a tertiary hospital from January 2016 to December 2018. CA-AKI was defined as an increase in serum creatinine ≥50% or 0.3 mg/dL within 48 h after contrast medium exposure. Results: During hospitalization, 198 patients (11.7%) developed CA-AKI. Restricted cubic spline (RCS) and receiver operating characteristic (ROC) analysis demonstrated that SChE levels were negatively correlated with CA-AKI and had predictive value (AUC, 0.655; 95% CI, 0.613-0.697). Multivariable regression analysis showed that patients in low-SChE group (≤7.5 kU/L) had a higher risk of developing CA-AKI (OR, 1.80; 95% CI, 1.21-2.67) compared to those in the high-SChE group (>7.5 kU/L). Regarding prognosis, SChE levels were also negatively associated with long-term mortality and were capable of predicting 90-day mortality (AUC, 0.826; 95% CI, 0.760-0.892). Patients in the low-SChE group had significantly higher long-term mortality risks (HR, 2.56; 95% CI, 1.55-4.32). Mediation analyses further indicated that CA-AKI partially mediated the relationship between SChE and short-term mortality, with a mediation proportion of 12.79%. Conclusion: Low SChE is an independent risk factor for CA-AKI and a poor prognosis after PCI. Short-term mortality associated with SChE levels is partially mediated through the occurrence of CA-AKI. It is recommended that clinicians evaluate SChE levels prior to PCI and adjust hydration therapy according to SChE levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.